President Donald Trump announced on Friday that his administration has reached new agreements with nine major pharmaceutical companies aimed at lowering prescription drug prices in the United States. Speaking at the White House, Trump framed the deals as a significant win for consumers who long have paid far more for medications than patients in other wealthy countries. He described the changes as part of a broader effort to overhaul what he characterizes as an unfair pharmaceutical pricing system and to bring U.S. costs in line with lower international benchmarks.
Central to the agreements is a “most favored nation” pricing model. Under this approach, participating drugmakers agree to sell their medications—both to the government (such as Medicaid) and to certain Americans—at prices no higher than those charged in other developed countries. Trump emphasized that this strategy would immediately make drugs more affordable and prevent companies from charging Americans disproportionately high rates simply because of the size and profitability of the U.S. market.
The nine companies involved in Friday’s announcement include Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi. These firms agreed to restructure pricing for key medications and to offer certain drugs at globally competitive rates. In return, the administration provided incentives such as a three‑year reprieve from potential pharmaceutical tariffs and commitments to invest in U.S. manufacturing and research.
The agreements also lay the groundwork for expanded direct‑to‑consumer access to lower prices. A new federal platform, TrumpRx.com, is set to launch in early 2026 to help uninsured and cash‑pay patients purchase medications at discounted prices negotiated under these deals. For example, one White House briefing cited specific price cuts for drugs like Merck’s diabetes medication, which could be offered substantially below current U.S. list prices through the TrumpRx system.
This latest round of deals builds on earlier actions by the administration aimed at reducing drug costs. In past months, Trump had pressed a larger group of drugmakers to adopt most‑favored‑nation pricing and reached voluntary agreements with companies such as Pfizer, AstraZeneca, Eli Lilly, and Novo Nordisk. In some of these earlier deals, prices for high‑cost medications—including weight‑loss and diabetes drugs—were substantially reduced when sold through direct‑to‑consumer channels.
While the White House and Trump cast these agreements as historic victories, questions remain about how broadly and how quickly savings will reach patients. Critics note that tying prices to international benchmarks and implementing new platforms involves complex logistics and may take time before consumers see noticeable decreases at the pharmacy. Additionally, industry observers have pointed out that while Medicaid and uninsured populations may benefit directly, the overall impact on the wider healthcare system and drug innovation remains to be fully assessed.
